JP2004506718A5 - - Google Patents

Download PDF

Info

Publication number
JP2004506718A5
JP2004506718A5 JP2002521200A JP2002521200A JP2004506718A5 JP 2004506718 A5 JP2004506718 A5 JP 2004506718A5 JP 2002521200 A JP2002521200 A JP 2002521200A JP 2002521200 A JP2002521200 A JP 2002521200A JP 2004506718 A5 JP2004506718 A5 JP 2004506718A5
Authority
JP
Japan
Prior art keywords
trifluoromethyl
methyl
lower alkyl
bis
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002521200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004506718A (ja
JP4053877B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/008686 external-priority patent/WO2002016324A1/en
Publication of JP2004506718A publication Critical patent/JP2004506718A/ja
Publication of JP2004506718A5 publication Critical patent/JP2004506718A5/ja
Application granted granted Critical
Publication of JP4053877B2 publication Critical patent/JP4053877B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002521200A 2000-08-08 2001-07-27 4−フェニル−ピリジン誘導体 Expired - Lifetime JP4053877B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117003 2000-08-08
PCT/EP2001/008686 WO2002016324A1 (en) 2000-08-08 2001-07-27 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2004506718A JP2004506718A (ja) 2004-03-04
JP2004506718A5 true JP2004506718A5 (cg-RX-API-DMAC7.html) 2005-03-03
JP4053877B2 JP4053877B2 (ja) 2008-02-27

Family

ID=8169466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002521200A Expired - Lifetime JP4053877B2 (ja) 2000-08-08 2001-07-27 4−フェニル−ピリジン誘導体

Country Status (36)

Country Link
US (1) US6770637B2 (cg-RX-API-DMAC7.html)
EP (1) EP1309559B1 (cg-RX-API-DMAC7.html)
JP (1) JP4053877B2 (cg-RX-API-DMAC7.html)
KR (1) KR100518201B1 (cg-RX-API-DMAC7.html)
CN (1) CN1293056C (cg-RX-API-DMAC7.html)
AR (1) AR030324A1 (cg-RX-API-DMAC7.html)
AT (1) ATE328871T1 (cg-RX-API-DMAC7.html)
AU (2) AU1211802A (cg-RX-API-DMAC7.html)
BR (1) BR0113173A (cg-RX-API-DMAC7.html)
CA (1) CA2418868C (cg-RX-API-DMAC7.html)
CZ (1) CZ2003684A3 (cg-RX-API-DMAC7.html)
DE (1) DE60120419T2 (cg-RX-API-DMAC7.html)
DK (1) DK1309559T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034475A (cg-RX-API-DMAC7.html)
ES (1) ES2264706T3 (cg-RX-API-DMAC7.html)
GT (1) GT200100160A (cg-RX-API-DMAC7.html)
HR (1) HRP20030055A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0301671A3 (cg-RX-API-DMAC7.html)
IL (2) IL154079A0 (cg-RX-API-DMAC7.html)
JO (1) JO2371B1 (cg-RX-API-DMAC7.html)
MA (1) MA27680A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001143A (cg-RX-API-DMAC7.html)
MY (1) MY128993A (cg-RX-API-DMAC7.html)
NO (1) NO324841B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ523751A (cg-RX-API-DMAC7.html)
PA (1) PA8524401A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020332A1 (cg-RX-API-DMAC7.html)
PL (1) PL359849A1 (cg-RX-API-DMAC7.html)
PT (1) PT1309559E (cg-RX-API-DMAC7.html)
RU (1) RU2277087C2 (cg-RX-API-DMAC7.html)
SI (1) SI1309559T1 (cg-RX-API-DMAC7.html)
TW (1) TWI259180B (cg-RX-API-DMAC7.html)
UY (1) UY26872A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002016324A1 (cg-RX-API-DMAC7.html)
YU (1) YU8703A (cg-RX-API-DMAC7.html)
ZA (1) ZA200300614B (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103545B1 (en) * 1999-11-29 2003-11-05 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
EP1688408A3 (en) * 2002-08-08 2007-08-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
NZ537952A (en) * 2002-08-08 2008-04-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
JP2007521276A (ja) * 2003-06-25 2007-08-02 スミスクライン・ビーチャム・コーポレイション Nk−2およびnk−3として用いるための4−カルボキサミドキノリン誘導体
KR100744859B1 (ko) 2003-07-03 2007-08-01 에프. 호프만-라 로슈 아게 정신분열증 치료를 위한 이중 nk1/nk3 길항물질
EP1745034A1 (en) 2004-02-11 2007-01-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
CN1997371A (zh) * 2004-07-06 2007-07-11 泽农医药公司 烟酰胺衍生物及其作为治疗剂的用途
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Nk-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
CN1984891B (zh) * 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1855655A2 (en) 2005-02-25 2007-11-21 F. Hoffmann-Roche AG Tablets with improved drug substance dispersibility
JP4712865B2 (ja) * 2005-04-06 2011-06-29 エフ.ホフマン−ラ ロシュ アーゲー Cb1逆アゴニストとしてのピリジン−3−カルボキサミド誘導体
WO2006113261A2 (en) * 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2007021982A2 (en) * 2005-08-11 2007-02-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PL1928886T3 (pl) 2005-09-09 2011-09-30 Nerre Therapeutics Ltd Pochodne pirydyny i ich zastosowanie w leczeniu zaburzeń psychotycznych
SI1945632T1 (sl) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
IN2014KN02423A (cg-RX-API-DMAC7.html) 2006-04-07 2015-05-01 Vertex Pharma
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
EP2164840A2 (en) 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
PT2225230T (pt) 2007-12-07 2016-12-07 Vertex Pharma Formas sólidas de ácido 3-(6(1-(2,2-difluorobenzo[d][1,3] dioxol-5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico
PL2639223T3 (pl) 2007-12-07 2017-09-29 Vertex Pharmaceuticals Incorporated Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych
NZ620944A (en) 2008-02-28 2015-02-27 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA107088C2 (xx) * 2009-09-11 2014-11-25 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
WO2011054773A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Novel lactam compounds
FR2954315B1 (fr) * 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
EP2555754B1 (en) 2010-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
KR20130056244A (ko) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
WO2013049559A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
LT2776427T (lt) 2011-11-08 2017-04-10 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
HK1209318A1 (en) 2012-07-16 2016-04-01 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
BR112016009811A2 (pt) * 2013-11-08 2017-12-05 Kissei Pharmaceutical derivado de carboximetil piperidina
KR102280372B1 (ko) 2013-11-12 2021-07-22 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
DK3221692T3 (da) 2014-11-18 2021-08-23 Vertex Pharma Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi
US10538491B2 (en) * 2015-03-16 2020-01-21 Vanderbilt University 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
CN108712913B (zh) * 2015-12-22 2022-06-24 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
US12473260B2 (en) * 2019-11-15 2025-11-18 KaNDy Therapeutics Limited Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56106286A (en) 1980-01-28 1981-08-24 Nippon Musical Instruments Mfg Electronic musical instrument
EP0103545A3 (en) 1982-09-13 1984-10-03 Arc Technologies Systems, Ltd. Electrode for arc furnaces
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
ATE144498T1 (de) * 1990-05-31 1996-11-15 Pfizer Herstellung von substituierten piperidinen
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
WO1995018124A1 (en) 1993-12-29 1995-07-06 Merck Sharp & Dohme Limited Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EP0733632B1 (en) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
AU4885097A (en) * 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
HUP0104933A3 (en) * 1999-01-07 2003-12-29 Warner Lambert Co Antiviral method using mek inhibitors
SI1035115T1 (en) * 1999-02-24 2005-02-28 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
CN1131212C (zh) * 1999-02-24 2003-12-17 弗·哈夫曼-拉罗切有限公司 苯基-和吡啶基衍生物
EP1222800A2 (en) * 1999-10-14 2002-07-17 Telefonaktiebolaget LM Ericsson (publ) System and method of retrieving voice mail messages in a telecommunications network
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
EP1103545B1 (en) * 1999-11-29 2003-11-05 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide

Similar Documents

Publication Publication Date Title
JP2004506718A5 (cg-RX-API-DMAC7.html)
CA2418868A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
JP2004504301A5 (cg-RX-API-DMAC7.html)
RU2003105805A (ru) Производные 4-фенилпиридина в качестве антагонистов рецепторов нейрокинина-1
JP2001526220A5 (cg-RX-API-DMAC7.html)
JP5184376B2 (ja) ベンズアミドおよびヘテロアレーン誘導体
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2018519323A5 (cg-RX-API-DMAC7.html)
JP2004529931A5 (cg-RX-API-DMAC7.html)
JP2005501120A5 (cg-RX-API-DMAC7.html)
JP2007532651A5 (cg-RX-API-DMAC7.html)
JP2019537605A5 (cg-RX-API-DMAC7.html)
JP2021504443A5 (cg-RX-API-DMAC7.html)
WO2005123680B1 (en) Six-membered heterocycles useful as serine protease inhibitors
JP2004504400A5 (cg-RX-API-DMAC7.html)
PH12015502114B1 (en) 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
RU2010129541A (ru) Карбоксил- или гидроксилзамещенные производные бензимидазола
JP2007502264A5 (cg-RX-API-DMAC7.html)
JP2013520473A5 (cg-RX-API-DMAC7.html)
RU2013132930A (ru) Производное пиразола
JP2010539110A5 (cg-RX-API-DMAC7.html)
JP2019531279A5 (cg-RX-API-DMAC7.html)
JP2008516902A5 (cg-RX-API-DMAC7.html)
CA2416874A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists